BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe
文献类型：期刊论文
| 作者 | Bai, Zhaoshi1; Gao, Meiqi1; Zhang, Huijuan1; Guan, Qi2; Xu, Jingwen1; Li, Yao1; Qi, Huan3; Li, Zhengqiang1; Zuo, Daiying1; Zhang, Weige2 |
| 刊名 | CANCER LETTERS
 |
| 出版日期 | 2017-08-28 |
| 卷号 | 402页码:81-92 |
| 关键词 | Cbsis Multidrug Resistance P-glycoprotein Apoptosis-resistance Mitotic Catastrophe |
| DOI | 10.1016/j.canlet.2017.05.016 |
| 英文摘要 | Multidrug resistance (MDR) interferes with the efficiency of chemotherapy. Therefore, developing novel anti-cancer agents that can overcome MDR is necessary. Here, we screened a series of colchicine binding site inhibitors (CBSIs) and found that 5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) displayed potent cytotoxic activity against both A549 and A549/Taxol cells. We further explored the underlying mechanisms and found that BZML caused mitosis phase arrest by inhibiting tubulin polymerization in A549 and A549/Taxol cells. Importantly, BZML was a poor substrate for P-glycoprotein (P-gp) and inhibited P-gp function by decreasing P-gp expression at the protein and mRNA levels. Cell morphology changes and the expression of cycle- or apoptosis-related proteins indicated that BZML mainly drove A549/Taxol cells to die by mitotic catastrophe (MC), a p53-independent apoptotic-like cell death, whereas induced A549 cells to die by apoptosis. Taken together, our data suggest that BZML is a novel colchicine binding site inhibitor and overcomes MDR in A549/Taxol cells by inhibiting P-gp function and inducing MC. Our study also offers a new strategy to solve the problem of apoptosis-resistance. (C) 2017 Elsevier B.V. All rights reserved. |
| 语种 | 英语 |
| WOS记录号 | WOS:000406168800009 |
| 源URL | [http://cas-ir.dicp.ac.cn/handle/321008/152036]  |
| 专题 | 大连化学物理研究所_中国科学院大连化学物理研究所 |
| 作者单位 | 1.Shenyang Pharmaceut Univ, Dept Pharmacol, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China 2.Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China 3.Chinese Acad Sci, Dalian Inst Chem Phys, Sci Res Ctr Translat Med, Dalian 116023, Peoples R China |
| 推荐引用方式 GB/T 7714 | Bai, Zhaoshi,Gao, Meiqi,Zhang, Huijuan,et al. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe[J]. CANCER LETTERS,2017,402:81-92. |
| APA | Bai, Zhaoshi.,Gao, Meiqi.,Zhang, Huijuan.,Guan, Qi.,Xu, Jingwen.,...&Wu, Yingliang.(2017).BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.CANCER LETTERS,402,81-92. |
| MLA | Bai, Zhaoshi,et al."BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe".CANCER LETTERS 402(2017):81-92. |
入库方式： OAI收割
来源：大连化学物理研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。